Tesofensine: The Triple Monoamine Reuptake Inhibitor for Stubborn Fat Loss

In 2008, Arne Astrup and colleagues published a Phase 2 trial in The Lancet on a Danish-developed compound called tesofensine. Obese patients on 1 mg/day for 24 weeks lost an average of 12.8 kg versus 2.2 kg for placebo. The effect size was roughly double what the FDA-approved obesity drugs of the era could produce. The market expected a Phase 3 program. Within two years, Phase 3 development had stalled. Cardiovascular signals — heart rate increases averaging 7.8 bpm at the high dose, blood pressure elevation in a subset of patients — and psychiatric signals (mood, anxiety, irritability) raised regulatory concerns that the post-sibutramine, post-rimonabant FDA was no longer willing to absorb in an obesity indication.

NeuroSearch, the Danish company that developed tesofensine, eventually sold the asset. Subsequent development has been pursued in markets with different regulatory thresholds — Mexico approved tesofensine for obesity, and the drug is available there under brand names including Tesomet (a tesofensine + metoprolol combination intended to address the heart rate issue) and Tesogen. Outside Mexico and a handful of other markets, tesofensine exists in the research-chemical gray market, clustered in the same vendor catalogs as peptides despite not being a peptide.

The drug is in a strange position. The efficacy is real. The safety concerns are real. The regulatory rejection in the US is real. The off-label and gray-market use is real. What follows is what is known.

What Tesofensine Is — Not a Peptide#

The name on the research-chemical sites is misleading. Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor — the compound class abbreviated TRI. Its mechanism inhibits the reuptake of norepinephrine, dopamine, and serotonin, increasing synaptic concentrations of all three monoamines.

This mechanism is shared (in different ratios) by older drugs:

Bupropion — norepinephrine and dopamine reuptake inhibition (NDRI), approved for depression and smoking cessation, with mild weight-loss effects.

Sibutramine — serotonin and norepinephrine reuptake inhibition, FDA-approved for obesity in 1997, withdrawn in 2010 due to cardiovascular adverse events.

SSRIs and SNRIs — serotonin or serotonin+norepinephrine reuptake inhibitors, mostly used for psychiatric indications.

Tesofensine adds dopamine reuptake inhibition to the SNRI mechanism, producing a triple-action profile that increases satiety, reduces food intake, and increases energy expenditure. The dopamine component is part of why the weight loss effect exceeds simpler appetite suppressants — and also part of why the cardiovascular and psychiatric signals are stronger.

The clustering of tesofensine with the peptide world is a market artifact, not a pharmacological reality. Users approaching tesofensine should understand they are dealing with a stimulant-adjacent small molecule, not a peptide.

The Phase 2 Data — TIPO-1 and TIPO-2#

The Astrup 2008 Lancet publication is the canonical efficacy citation. The TIPO-1 trial randomized obese patients to placebo or tesofensine at 0.25, 0.5, or 1.0 mg/day for 24 weeks, with a 12-week placebo run-in followed by a hypocaloric diet. The results:

Placebo: 2.2 kg weight loss 0.25 mg: 6.7 kg 0.5 mg: 11.3 kg 1.0 mg: 12.8 kg

The dose-response was clean. The effect at 0.5 mg approximated what well-tolerated approved drugs could achieve; the effect at 1.0 mg substantially exceeded available alternatives.

The safety findings were also dose-dependent:

Resting heart rate increased by 7.8 bpm at 1.0 mg/day on average. This was the cardiovascular signal the FDA found unacceptable in chronic obesity use.

Systolic blood pressure increased in a subset, particularly at the 1.0 mg dose.

Psychiatric adverse events — mood changes, anxiety, sleep disturbance — were reported more frequently in the higher-dose groups.

The TIPO-2 trial extended observation and confirmed the efficacy signal but did not resolve the cardiovascular concern.

The Sjödin 2010 metabolism paper added mechanistic detail: tesofensine increased 24-hour energy expenditure modestly and reduced appetite substantially, with the satiety effect being the dominant driver of weight loss. The drug does not work primarily by burning more calories; it works primarily by making the patient eat less.

The 2008 Obesity paper documented the weight loss findings that initially drew attention to tesofensine — Parkinson's and Alzheimer's patients in CNS trials had lost meaningful weight as an unexpected effect, which prompted the obesity development program.

Why the FDA Did Not Approve#

The regulatory context matters. By the time tesofensine was approaching Phase 3, the FDA had withdrawn sibutramine (2010) over cardiovascular concerns and rejected rimonabant (2007) over psychiatric concerns. The bar for obesity drug safety had risen. A drug producing 7.8 bpm heart rate increases and detectable psychiatric signals in chronic use — even with strong weight loss efficacy — was now in a different risk-benefit position than it would have been a decade earlier.

NeuroSearch halted Phase 3 development in 2010-2011. The asset was acquired by Saniona, a Danish biotech that continued development in select markets. Saniona pursued the Mexican regulatory pathway, which approved tesofensine (as Tesomet) for obesity in 2020.

The Mexican approval is real but limited in implication. Mexican regulatory standards differ from FDA standards, and the approval does not constitute Western consensus on the drug. The Tesomet formulation (tesofensine + metoprolol) is an attempt to address the cardiovascular signal by co-administering a beta-blocker; the combination is not approved in any Western market.

The honest position: tesofensine is an effective weight loss drug with a cardiovascular safety signal that has prevented Western approval. Mexico's approval reflects a different regulatory calculus. Users sourcing tesofensine through research-chemical channels are choosing a drug whose efficacy is well-established and whose safety constraints are also well-established.

Comparison to Other Obesity Pharmacotherapy#

The 2026 obesity landscape is dominated by GLP-1 agonists. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce 15-22% weight loss over 68 weeks in trial data, with a safer cardiovascular profile and FDA approval. These are now the first-line pharmacotherapy options for medically supervised weight loss.

Against this backdrop, tesofensine's position has shifted:

Versus GLP-1 agonists: GLP-1 drugs match or exceed tesofensine on weight loss efficacy with better safety. For most patients seeking medically supervised weight loss, GLP-1 therapy is the better option.

Versus phentermine: phentermine is FDA-approved (DEA Schedule IV) for short-term obesity use. Tesofensine has stronger efficacy at full dose but longer half-life and stronger cardiovascular signals. Phentermine is short-acting, can be cycled, and is legally accessible with prescription.

Versus bupropion-naltrexone (Contrave): Contrave produces modest weight loss with a milder cardiovascular profile. Tesofensine produces more weight loss with a stronger cardiovascular profile.

Versus stimulant abuse (off-label amphetamine, methylphenidate): some users self-medicate for weight loss with prescribed or non-prescribed stimulants. Tesofensine has a cleaner once-daily PK profile and lower abuse liability than short-acting stimulants but carries similar cardiovascular concerns.

The realistic user profile for tesofensine in 2026: patients who have not responded to GLP-1 therapy or cannot tolerate it, patients in markets where tesofensine is regulated and GLP-1 access is limited, or users seeking a combination approach (the GLP-1 + tesofensine combination is being explored in Mexican clinical practice but is not FDA-territory).

The Mexican Pathway and Tesomet#

The trajectory of tesofensine after NeuroSearch's exit deserves attention because it shapes the current sourcing landscape.

Saniona acquired the asset and pursued Mexican regulatory approval rather than re-attempting FDA review. The Mexican Federal Commission for Protection against Sanitary Risks (COFEPRIS) approved tesofensine in 2020. The approved product is marketed under brand names that include Tesomet (a fixed combination of 0.5 mg tesofensine plus 50 mg metoprolol succinate). The metoprolol combination is designed specifically to blunt the heart rate elevation that tesofensine produces — a clever pharmaceutical workaround for the safety signal that had blocked Western approval.

The Mexican approval is consequential for users sourcing tesofensine because it means a regulated pharmaceutical-grade product exists. Patients in Mexico can receive tesofensine through prescription channels with quality control and physician oversight. This is the cleanest supply source available globally.

For users outside Mexico, the regulatory situation has not changed. The FDA has not reviewed tesofensine for obesity. The EMA has not approved it. The drug remains a research chemical in most Western jurisdictions, with the associated sourcing risk: variable purity, incorrect identity, contamination. Lab testing of research-chemical tesofensine has found products ranging from 80% purity to outright misidentification.

The implication for users: anyone considering tesofensine should strongly prefer the Mexican pharmaceutical pathway over research-chemical sourcing if access is possible. The cost-quality differential is significant.

The Cardiovascular Conversation#

This is the variable that matters most.

Tesofensine reliably increases resting heart rate. The 1 mg dose produced average increases of 7.8 bpm in TIPO-1. Lower doses (0.25-0.5 mg) produced smaller increases. The effect is dose-dependent and consistent.

Blood pressure effects are more variable. Some patients show clear increases; others show stable or slightly decreased pressure as weight loss progresses. The net cardiovascular load is the integration of HR effects, BP effects, and metabolic improvements from weight loss.

For a healthy normotensive user without cardiovascular risk factors, a 5-8 bpm heart rate increase is unlikely to cause acute harm. For a user with hypertension, atherosclerosis, arrhythmia history, or other cardiovascular pathology, the same increase could meaningfully shift risk.

The conservative monitoring protocol: daily resting heart rate and blood pressure measurement, baseline ECG before starting, repeat ECG at 4-8 weeks, immediate stop if heart rate increases beyond 100 bpm at rest, blood pressure exceeds 140/90 sustained, palpitations, chest pain, or new symptoms of any cardiac type.

For users tracking cardiovascular adaptation through hrv, tesofensine typically produces measurable HRV reduction reflecting increased sympathetic tone. Persistent HRV decline is a stop signal. The cortisol-am marker is also worth tracking — tesofensine can elevate stress hormones in some users.

Psychiatric and Sleep Considerations#

The dopamine and norepinephrine reuptake inhibition produces stimulant-adjacent psychiatric effects in some users:

Mood elevation in some, anxiety or irritability in others Sleep disturbance, particularly if dosed later in the day Reduced appetite that can extend to anhedonic features in some users Rare but real reports of mood instability or worsening of underlying psychiatric conditions

Anyone with a history of bipolar disorder, psychotic disorders, severe anxiety, or eating disorders should not use tesofensine. Anyone with a history of stimulant abuse should not use tesofensine.

Sleep impact is significant. Tesofensine should be dosed in the morning to minimize sleep interference. Even with morning dosing, the long half-life (approximately 9 days) means accumulated drug levels can affect sleep architecture. The sleep-deprivation-testosterone framework applies — chronic sleep disruption compounds metabolic and hormonal problems that fat loss is intended to address. A user losing weight on tesofensine while developing insomnia is fighting a multi-front battle that may not net positive.